Study on Real World Outcomes of Pembrolizumab in Black Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria

• Be willing and able to provide written consent to participate.
• Be 18 years or older.
• Identify as Black or African American.
• Have a performance status score of 0 to 2, indicating full activity or some restriction in strenuous activities.
• Have a confirmed diagnosis of advanced or metastatic non-small cell lung cancer (NSCLC).
• Not have received treatment for advanced/metastatic/recurrent NSCLC before.
• Have no known mutations in EGFR, ALK, or ROS1 genes.
• Be eligible to receive first-line therapy for advanced/metastatic NSCLC.
• Have a test result for PDL1 status.
• Have recovered from any side effects of previous cancer treatments to a mild level or baseline.
• Have adequate organ function as determined by medical tests.
• Women of childbearing potential must have a negative pregnancy test before starting treatment and agree to use effective birth control during the study and for a specified period after.
• Men must agree to use barrier contraception during the study and for a specified period after.

Exclusion Criteria

• Not planning or eligible to receive pembrolizumab with or without chemotherapy.
• History of organ transplant.
• Have received prior chemotherapy or immune therapy for advanced/metastatic lung cancer.
• Have an immune deficiency or are on high-dose steroids or other immunosuppressive therapy.
• Have an active autoimmune disease requiring treatment in the past two years.
• Have an active infection needing treatment.
• Have any condition or treatment that could interfere with the study or increase risk.
• Have received a live vaccine within 30 days before starting the study.
• Have a history of severe lung inflammation or current lung disease.
• Have untreated brain metastases or cancer in the brain lining.
• Have severe allergies to pembrolizumab or related drugs.